Clarivate Q4 Earnings Call Highlights

Core Insights - Clarivate is experiencing a "positive inflection point" after meeting its full-year financial guidance for the first time since 2019, with nearly 2% organic annual contract value (ACV) growth and over $1 billion in adjusted EBITDA for 2025 [2][5][6] Financial Performance - For 2025, Clarivate reported nearly 2% organic ACV growth, improved organic recurring revenue mix to 88%, and generated over $1 billion in adjusted EBITDA along with $365 million in free cash flow [6][7] - Fourth-quarter revenue was $617 million, with full-year revenue totaling $2.455 billion, primarily influenced by inorganic changes due to divestitures [7] - Adjusted diluted EPS for the fourth quarter was $0.20, reflecting a $0.02 sequential increase, with operating cash flow of $160 million [8] AI Strategy - Clarivate is implementing an "Intelligence Amplified" strategy, focusing on AI assistants and workflow agents, with 97% of revenue derived from proprietary solutions enhanced by AI [2][3][9] - The company has launched 10 AI assistants and AI-native solutions, now utilized by over 4,000 institutions, and expects to release more than 10 additional AI solutions in the coming year [10][12] Business Segments - The Life Sciences & Healthcare (LS&H) business is under review for potential sale to enhance focus on Academia & Government (A&G) and Intellectual Property (IP) markets, although 2026 guidance assumes LS&H will be retained for the full year [4][16] - In A&G, the segment achieved 2% organic ACV growth despite funding challenges, with a shift towards a recurring revenue model [10] - The IP segment is undergoing a turnaround with new leadership and AI product launches, showing a 270 basis points year-over-year improvement in annuities revenue [11] Capital Allocation and Leverage - Clarivate's capital allocation strategy includes $225 million in share repurchases and $200 million in bond retirements, maintaining net leverage at approximately four times [14][15] - For 2026, the company aims for 2-3% organic ACV growth, margin expansion to nearly 43%, and a free cash flow target of approximately $400 million [3][17]